BMS’s Opdivo meets co-primary endpoint in colorectal cancer trial
Despite Opdivo’s success in combination trials, Bristol-Myers Squibb faces challenges as Opdivo’s European and U.S. patents expire in 2026 and 2028, respectively, threatening sales growth. There is. Credit: Dennis Diatel, via ShutterStock. Bristol-Myers Squibb (BMS) announced that its Phase III CheckMate-8HW study of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of metastatic […]
Oncolytics Biotech Inc. Announces Anal Cancer Cohort of Peraleolep and Atezolizumab Goblet Phase 1/2 Clinical Trial Meets Efficacy Criteria – November 9, 2023, 7:01 a.m. EST
Oncolytics Biotech Inc. announces positive interim results from the Phase 1/2 GOBLET trial evaluating the combination of perolep and atezolizumab in second-line patients with unresectable anal canal squamous cell carcinoma, led by Dirk Arnold, MD. It was announced that it was announced. Director of the Asklepios Oncology Center in Hamburg and principal investigator of the […]
Oncolytics Announces Anal Cancer Cohort of GOBLET Phase 1/2 Study of Peralolep and Atezolizumab Meets Efficacy Success Criteria
Data for the combination of peralolep and atezolizumab exceeds previous controlled trials with an objective response rate of 37.5%, including complete responses. SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), an oncology-focused clinical-stage immunotherapy company, today announced that gave a presentation on intermediate therapeutic drugs. Results […]
Oncolytic therapy meets efficacy criteria in third-line colorectal cancer cohort of GOBLET study
The results met the efficacy criteria for expanded registration and supported Perolep’s mechanism of action. san diego and Calgary, Alabama, October 23, 2023 /PRNewswire/ — Oncolytic Biotechnology® Inc. (NASDAQ: Oncy(Oncolytics) (TSX: ONC), an oncology-focused clinical-stage immunotherapy company, today announced that microsatellite Discuss metastatic colorectal cancer (CRC) regardless of its instability status. madrid, spain. Oncolytics_Biotech_Grey “The […]